Apellis Pharmaceuticals, Inc. (APLS)
21.75
-0.25
(-1.14%)
USD |
NASDAQ |
Jan 23, 16:00
21.76
+0.01
(+0.05%)
After-Hours: 20:00
Apellis Pharmaceuticals Research and Development Expense (TTM): 297.98M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amicus Therapeutics, Inc. | 142.29M |
| Alnylam Pharmaceuticals, Inc. | 1.248B |
| Ionis Pharmaceuticals, Inc. | 879.75M |
| Fortress Biotech, Inc. | 22.21M |
| Sarepta Therapeutics, Inc. | 1.389B |